Does removing blood vessels boost survival in bile duct cancer surgery?
NCT ID NCT07311798
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study reviews past medical records of 300 people who had surgery for a rare and aggressive bile duct cancer called hilar cholangiocarcinoma. It aims to see if also removing nearby blood vessels during the operation helps patients live longer and have fewer complications. The goal is to provide clearer guidance for surgeons and patients facing this difficult decision.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 300 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Feb 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population includes patients who underwent curative-intent surgery for hilar cholangiocarcinoma at the Department of Hepatobiliary and Pancreatic Surgery of our hospital between January 2010 and December 2024. Patients were included regardless of whether vascular resection was performed. All patients had a pathologically confirmed diagnosis of hilar cholangiocarcinoma and sufficient clinical and follow-up data for outcome analysis. Patients with distant metastasis, those who underwent only palliative or exploratory surgery, or those with incomplete medical records or missing key clinical or follow-up information were excluded. According to intraoperative findings, patients were categorized into vascular resection and non-vascular resection cohorts.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients who underwent surgical treatment at the Department of Hepatobiliary and Pancreatic Surgery of our hospital between January 2010 and December 2024, including those with or without concomitant vascular resection. * Pathologically confirmed diagnosis of hilar cholangiocarcinoma after surgery. * Complete clinical and follow-up data available for outcome analysis. Exclusion Criteria: * Patients with distant metastasis or who underwent only palliative or exploratory surgery. * Patients diagnosed preoperatively or intraoperatively with other types of biliary malignancies not located at the hilar region. * Patients with incomplete medical records or missing key clinical or follow-up data.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cholangiocarcinoma, hilar are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
The full official record for this study. This one lists no contact details, but it is the first place any would appear.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.